CDC Updates Immunization Schedules: COVID-19 & Chickenpox Vaccine Changes

The Centers for Disease Control and Prevention (CDC) has updated its immunization schedules, shifting to an individual-based approach for COVID-19 vaccination and recommending a standalone vaccine for chickenpox (varicella) in toddlers. This marks a significant change in how the agency approaches these immunizations, moving away from broad recommendations towards decisions tailored to individual risk factors and clinical considerations. The updated schedules, reflecting recent recommendations from the Advisory Committee on Immunization Practices (ACIP), will be available on CDC.gov by October 7, 2025.

A Shift Towards Personalized COVID-19 Vaccine Decisions

The most notable change concerns COVID-19 vaccination. Previously, the CDC issued blanket recommendations for perpetual boosters, a strategy that, according to Acting Director of the CDC and Deputy Secretary of Health and Human Services Jim O’Neill, “deterred health care providers from talking about the risks and benefits of vaccination for the individual patient or parent.” The new approach, termed “shared clinical decision-making,” emphasizes a conversation between healthcare providers – including physicians, nurses, and pharmacists – and patients to determine the most appropriate course of action. This decision should be based on individual risk factors for severe COVID-19, as defined by the CDC, and the characteristics of the vaccine itself.

This shift comes after a decline in booster uptake. While Operation Warp Speed (OWS) initially achieved an estimated 85% vaccination rate for the primary COVID-19 series among U.S. Adults, only 23% of adults followed the CDC’s most recent seasonal booster recommendation, according to the agency’s National Immunization Survey. Widespread concerns about the safety and efficacy of boosters, coupled with the increasing population immunity acquired through prior infection and vaccination, likely contributed to this decline. ACIP’s recommendation acknowledges that the risk-benefit profile of vaccination differs significantly; it’s most favorable for those at increased risk of severe COVID-19 and least favorable for those not at increased risk.

Standalone Varicella Vaccine for Toddlers: Reducing Febrile Seizure Risk

Alongside the changes to COVID-19 guidance, the CDC is now recommending that toddlers receive the chickenpox vaccine as a standalone immunization, rather than in combination with the measles, mumps, and rubella (MMR) vaccine. This recommendation stems from evidence presented to ACIP by the CDC Immunization Safety Office. The data indicates that healthy toddlers aged 12-23 months have a higher risk of experiencing febrile seizures – convulsions triggered by fever – seven to ten days after receiving the combined MMRV vaccine (measles, mumps, rubella, and varicella) compared to those who receive the varicella vaccine separately. The combination vaccine doubles the risk of these seizures without providing any additional protection against chickenpox. You can find the presentation detailing this evidence here.

Understanding Shared Clinical Decision-Making

The move to individual-based decision-making for COVID-19 vaccination represents a broader trend in public health towards recognizing the complexities of individual risk profiles. It’s important to understand what this means in practice. Unlike age-based recommendations, which are effortless to apply universally, shared clinical decision-making requires healthcare providers to consider a range of patient-specific factors. These include underlying health conditions that increase the risk of severe COVID-19 (as outlined by the CDC), as well as the characteristics of the vaccine itself and the latest available evidence regarding its benefits and risks. This approach ensures that vaccination decisions are informed by a thorough assessment of each patient’s unique circumstances.

Access to Immunizations Remains Consistent

Despite the shift in recommendation strategy, access to vaccines will remain consistent. The CDC emphasizes that individual-based decision-making does not affect coverage through existing payment mechanisms. Immunizations will continue to be available through entitlement programs like Medicare, Medicaid, the Children’s Health Insurance Program, and the Vaccines for Children Program, as well as through insurance plans regulated by the Affordable Care Act.

What Does This Mean for Public Health Surveillance?

These changes likewise have implications for public health surveillance. As vaccination decisions become more individualized, tracking overall immunization rates and identifying populations with lower coverage will become more complex. The CDC will likely need to refine its surveillance systems to capture data on the factors influencing individual vaccination decisions, allowing for more targeted interventions to address disparities and ensure equitable access to protection. Continued monitoring of COVID-19 variants and their impact on disease severity will also be crucial to inform future vaccination recommendations.

The CDC’s updated immunization schedules reflect a growing understanding of the nuances of vaccine effectiveness and safety, and a commitment to empowering both healthcare providers and patients to make informed decisions. For the most up-to-date information, individuals should consult with their healthcare provider and refer to official updates from the CDC on CDC.gov.